By Zack Guzman
Canopy Growth (CGC) is planning to expand its investment in American cannabis.
The Canada-based cannabis company previously announced an investment of $100 million to $150 million to process and produce hemp in New York after securing a license from the state’s government officials in January. It now plans to increase the total investment in U.S. hemp to up to $500 million by adding hemp production in Rhode Island and two to three other states in the U.S., Canopy Growth CEO Bruce Linton told Yahoo Finance.
“We’ll do it state by state right now, because what has to happen is the state needs to regulate what is permissible for CBD,” Linton said. “So we’ll probably have three or four states that have big populations and progressive leadership who want to have hemp become part of their actual job creation industrial platform.”
The move to invest in a hemp processing facility in New York represented the company’s first large push into cannabis extraction and processing outside of Canada. Now, the extended push into U.S. hemp production makes Canopy Growth one of the major companies focused on the space since the passage of the farm bill earlier this year made growing hemp legal at a federal level, though production oversight is still largely left to individual states to decide.
Hemp, the cannabis sister species to marijuana, is coveted for its relatively higher concentration of CBD, or cannabidiol, the non-psychoactive compound that can’t get users high like THC in marijuana, but is thought to alleviate a range of issues including anxiety and insomnia. CBD sales have steadily risen as use in creams, lotion, tinctures and even beverages have gained popularity. Brightfield Group, a cannabis industry research firm, estimates the hemp-derived CBD market will grow to become a $22 billion market by 2022, but that’s not all that interests Linton.
“When you think hemp, you should think about the protein, you should think about the fiber, and you should think about the CBD,” Linton said. “And so when you start covering all those categories, it doesn’t take too long until you can see, ‘Wow there is a lot of potential yield on this.’ And so putting the money in means that you’re actually creating an intent to be there for long enough to do the science and get the reward.”
Beyond the necessary sourcing of CBD for CBD-infused beverages or other products, the reward that comes with being a major hemp processor at scale could also leave Canopy with usable byproducts. One separate hemp-focused startup is currently using hemp waste to produce plastics for cannabis companies’ packaging. It’s unclear if Canopy has similar plans, but it would seemingly be an efficiency boost for a company that operates entirely through the production chain from seed to sale.
Becoming a leader in cannabis
Canopy has also been bolstering its position through acquisitions. The company bought Evergreen, Colorado-based cannabis research startup ebbu in November 2018 for $330 million and gained control of more than 40 cannabis-related patent filings.
Canopy said the intellectual property it gained from the deal gave the company the potential “to vastly reduce the cost of CBD production.” Those cost savings could prove even more important as the company’s focus on hemp production becomes a more significant part of its business moving forward.